Picture EBD Group BIO-Europe Spring 2020 Paris BEU2020 650x75
Document › Details

Nabriva Therapeutics plc. (8/9/18). "Press Release: Nabriva Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights". Dublin.

Organisations Organisation Nabriva Therapeutics plc (Nasdaq: NBRV)
  Group Nabriva (Group)
  Organisation 2 Zavante Therapeutics Inc.
  Group Nabriva (Group)
Products Product lefamulin (BC-3781)
  Product 2 Contepo™ (fosfomycin for injection, previously ZTI-01 and ZOLYD)
Index term Index term Zavante Therapeutics–Nabriva: investment, 201807 acquisition upfront 8.2m Nabriva ordinary shares (=19.9% shareholding) + $97.5m milestones
Persons Person Schroeder, Ted (Nabriva 201807– CEO before Zavante Therapeutics + Cadence Pharmaceuticals + Élan)
  Person 2 Garrett, Dave (Nabriva 201709 Investor Relations)

Record changed: 2018-12-25


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Nabriva (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

» top